Eyetelligence, a Melbourne, Australia-based healthtech company that uses advanced AI and retinal imaging to screen for eye and systemic disease, raised $12 million (A$18M) in funding from New York-based investor Ascertain.
“I welcome the support of Ascertain, which sees the potential of Eyetelligence's technology for the US and is committed to identifying and accelerating the use of emerging AI technologies to drive significant health benefits globally,” said Professor Mingguang He, co-founder of Eyetelligence.
Eyetelligence has developed a suite of clinically validated and regulatory-approved AI-enabled products that are already being used in Australia, New Zealand, Europe, and Japan and are sold through Bupa Optical and George & Matilda, among others.
Eyetelligence will be rebranded and launched in the US as Optain, with the goal of offering non-invasive point-of-care technology to diagnose a range of diseases more rapidly and cost-effectively.
“The healthcare industry has made a concerted effort in recent years to shift treatment from reactive sick-care to proactive preventive care, but many of the legacy screening and diagnostic technologies used by clinicians today are expensive and inaccessible. Optain will accelerate that shift,” Optain CEO Jeff Dunkel said.
The Ascertain collaboration will accelerate the availability of Optain’s Australian technology in American markets. Eyetelligence will continue to expand under its current brand in Australia and other international markets.
Company: Eyetelligence Pty Ltd
Funding Month: May 2023
Lead Investors: Ascertain
Company Website: https://eyetelligence.ai/
Software Category: AI Decision Support Software
About the Company: Optain (Eyetelligence) Optain is transforming preventive health with AI-enabled software and hardware products that noninvasively diagnose eye and systemic health conditions in real time. Using the eye as a gateway to monitor whole person health, Optain’s AI-enabled portable retinal camera empowers clinicians to screen over 140 eyes and systemic early stages of development. The company's technology is based on the inventions of Dr. Mingguang He, from the University of Melbourne and the Centre for Eye Research Australia.
Source: Eyetelligence Press Release